Orlando Serani | Program Architect CAR-T, Advanced Cellular Therapies Supply Chain
Johnson & Johnson

Orlando Serani, Program Architect CAR-T, Advanced Cellular Therapies Supply Chain, Johnson & Johnson

As of May 2018, Orlando leads the program strategy for the recently announced  Chimeric Antigen Receptor T-Cells therapeutic area.  This includes digital  
strategies, supply chain network design, and supply chain capability  
development for this therapy platform, currently targeted as a last line of  
defense for multiple myeloma.  
Previously, Orlando was Vice President, Information Technology, Customer and  
Logistics Services: the logistics and customer services organization which serves  
all Johnson & Johnson businesses globally.  Additionally, he also led the  
technology organization of the Consumer Medical Devices supply chain,  
including diabetes, contact lenses, and vision surgery products and services.   
Orlando began his career with the Johnson & Johnson Consumer business in Italy  in 1988.  After a Foreign Service National assignment with the United States  
Information Agency in Rome, Italy from 1990 until 1992, he rejoined Johnson &  
Johnson’s Ortho-Clinical Diagnostics, where he held diverse positions in R&D,  
Sales and Marketing, and IT.  In 2010, as part of the announcement of the  
Johnson & Johnson enterprise supply chain, he led the development of strategies  to further establish and create new business services including safe and secure  
supply chain (i.e. anti-counterfeit, serialization, track and trace), enterprise-wide  internal and external technology standards (enterprise master data, GS1, UDI,  
RFID), and new channel management strategies (ecommerce, demand sensing,  
distribution and transportation optimization).


Day 3: Friday 21st May 2021 - Commercialisation, Pricing & Access @ 13:30

Overcoming pain points in the CGT value chain by creating a scalable and collaborative ecosystem

·This session will feature interviews with leaders in Biopharma and logistics as they discuss their pain points as they move cell and gene therapies into commercialization.
last published: 10/May/21 08:45 GMT

back to speakers